Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for LV Relaxation in Non-Diabetic Hypertension
NCT04203914Phase 4Completed
- Sponsor
- Yaoundé Central Hospital
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in hypertension (HTN), sponsored by Yaoundé Central Hospital. Primary endpoint: Left ventricular diastolic function at 6 weeks. Started Jan 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04203914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203914.